Dysport.
Since the commercial launch of Dysport in 1991, after 10 years of clinical studies on its predecessor formulations, this BTX-A product has shown great therapeutic promise with a good safety profile and low incidence of treatment failures. As with all BTX products, Dysport should not be seen as a generic equivalent but as a specific product with individual unit dosing requirements and side effect profiles. Its role as an important BTX-A molecule looks set to expand as new indications for botulinum toxin arise, and as the cosmetic usage of Dysport is approved in countries outside of South America.
Markey
Andrew C
AC
St. John's Institute of Dermatology, St. Thomas' Hospital, London SE17EH, UK. markeyoffice@aol.com
D019274:Botulinum Toxins, Type A / Q000737:chemistry / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy; D009135:Muscular Diseases / Q000188:drug therapy; D009465:Neuromuscular Agents / Q000737:chemistry / Q000627:therapeutic use*; D015595:Skin Aging / Q000187:drug effects
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A